Binding of human anti-DNA autoantibodies to reactive oxygen species modified-DNA and probing oxidative DNA damage in cancer using monoclonal antibody.
The binding of native and reactive oxygen species-modified DNA (ROS-DNA) to circulating antibodies in the serum of patients with various types of cancer has been investigated by competition enzyme-linked immunosorbent assay. Fifteen sera of 35 showed reactivity with native and/or ROS-DNA. Eleven of these showed higher binding to ROS-DNA (36-64% inhibition), whereas 1 showed higher reactivity with native DNA (nDNA) (42% inhibition). Three sera reacted with both native and ROS-DNA almost equally. Oxidative lesions in human genomic DNA were immunochemically detected using an anti-ROS-DNA monoclonal antibody (MAb) probe. Two of 3 DNA isolates from blood of breast cancer patients, 1 of 3 from lung cancer and 1 of 2 each from hepatocellular cancer and cancer of the gallbladder were reactive with the MAb. Higher recognition of ROS-DNA by circulating antibodies and DNA isolated from cancer patients by the MAb indicates increased oxidative stress leading to DNA damage. Our results suggest that ROS modification of DNA probably alters its immunogenicity leading to the generation of antibodies to ROS-DNA, probably by the activation of autoreactive cells. The induced antibodies against modified DNA are cross-reactive to native DNA.